Evidence map›Paper›PMID 30006674›Full record

Trial reportClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

Baseline

A M García Vicente, B González García, M Amo-Salas, I García Carbonero, J Cassinello Espinosa, J L Gómez-Aldaraví Gutierrez, L Suarez Hinojosa, Á Soriano Castrejón

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Interim and end-treatmentScientific reports · 2021
    Article
  8. Prognostic Value ofBiomedicines · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A M García VicenteNuclear Medicine Department, University General Hospital, C/Obispo Rafael Torija s/n, 13005, Ciudad Real, Spain. angarvice@yahoo.es.ORCID http://orcid.org/0000-0002-4660-0533
B González GarcíaNuclear Medicine Department, University General Hospital, C/Obispo Rafael Torija s/n, 13005, Ciudad Real, Spain.
M Amo-SalasDepartamento de Matemáticas, Universidad de Castilla La Mancha, Ciudad Real, Spain.
I García CarboneroS. Oncología Médica, Complejo Hospitalario de Toledo, Toledo, Spain.
J Cassinello EspinosaS. Oncología Médica, Hospital Universitario de Guadalajara, Guadalajara, Spain.
J L Gómez-Aldaraví GutierrezS. Oncología Médica, Hospital Universitario de Albacete, Albacete, Spain.
L Suarez HinojosaS. Oncología Médica, H. Manzanares, Ciudad Real, Spain.
Á Soriano CastrejónNuclear Medicine Department, University General Hospital, C/Obispo Rafael Torija s/n, 13005, Ciudad Real, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo establish the utility of baseline

methodsProspective, multicenter and non-randomized study (ChoPET-Rad study). FCH PET/CT and BS were performed before the initiation of

resultsForty patients were evaluated. The median PFS and OS were of 3.0 ± 2.3 and 23.0 ± 4.2 months, respectively. 33 patients progressed and 13 died during the follow-up. The extension of the bone disease by FCH PET/CT (p = 0.011, χ

conclusionFCH PET/CT and BS had prognostic aim in the prediction of OS. None clinical or imaging variable was able to predict the PFS, probably due to the high rate of progressive disease.

Indexed as

AgedAged, 80 and overBone NeoplasmsCholineHumansKaplan-Meier EstimateMaleMiddle AgedPositron Emission Tomography Computed TomographyProgression-Free SurvivalProportional Hazards ModelsProstatic Neoplasms, Castration-ResistantRadioisotopesRadionuclide ImagingRadiumCholinefluorocholineRadioisotopesRadiumradium Ra 223 dichloride18F-Fluorocholine PET/CT223Radium treatmentBone scintigraphyMetastatic prostate cancerPrognosis

Identifiers

PMID30006674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.